Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drug-maker Pfizer announced Saturday.
Pfizer Drug Helped Cancer Patients Regain Weight, Study Shows
Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.
6h
Boehringer, GSK, Pfizer Still Face Zantac Cases Despite Mistrial
An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...
4d
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...
3d
on MSN
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
1d
Pfizer Inc. stock outperforms competitors despite losses on the day
Shares of Pfizer Inc. PFE shed 0.27% to $29.75 Wednesday, on what proved to be an all-around dismal trading session for the ...
2d
Pfizer (PFE) Receives a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...
Business Wire
2d
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--
Pfizer
Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast ...
Yale Environment 360
11h
Internship Spotlight: Miguel Agreda ’25, Pfizer
Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...
3d
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...
9d
Pfizer: The Rally May Just Be Getting Started
Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...
10d
A mural honoring scientists hung in Pfizer’s NYC lobby for 60 years. Now it’s up for grabs
NEW YORK (AP) — A mural honoring ancient and modern figures in medicine that has hung in the lobby of Pfizer’s original New ...
2d
on MSN
Lightning Round: Buy more Pfizer, says Jim Cramer
Pfizer, First Solar, Six Flags, Equity Residential, Vertiv, Moderna, and Powell Industries. Donald Trump Suffers Major Blow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
India
New York Stock Exchange
United States
Ponsegromab
cachexia
Feedback